Who is eligible for clinical trial NCT07674745?

Participants must meet the protocol's inclusion criteria for Idiopathic Pulmonary Fibrosis. The stated age range is 40 Years to 85 Years. Confirm all requirements with the study coordinator.

Does clinical trial NCT07674745 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-06-29

Autoantibody Reduction Therapy for Progressive Idiopathic Pulmonary Fibrosis (NCT07674745)

Study of Therapeutic Plasma Exchange, Rituximab, and Intravenous Immunoglobulin for Progressive Idiopathic Pulmonary Fibrosis (STRIVE II)

🟡 Not Yet Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: University of Alabama at Birmingham

🩺 Plain-English Summary (8th-Grade Level)

This Phase IIb trial will compare effectiveness and safety of a multi-component autoantibody reduction therapy (AART), consisting of therapeutic plasma exchange (TPE), rituximab, and intravenous immunoglobulin (IVIg) for treatment of patients with progressive idiopathic pulmonary fibrosis (IPF).

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (9 items) and avoid the listed exclusions (22 items).

Location: University of Alabama at Birmingham — Birmingham, Alabama

Age range: 40 Years to 85 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Age between 40-85 years old.
A diagnosis of IPF that fulfills latest ATS/ERS Consensus Criteria.
A diagnosis of Progressive IPF (P-IPF), defined as a relative decrease of FVC%p \>10% during the preceding twelve months, and substantiated by replicate values at least three weeks apart.
Ability and willingness to give informed consent (no surrogates) and adhere to requirements.
Have eligibility confirmed by a consensus of trial investigators.
Is not now or has been in experimental regimen for at least 2 weeks (or 5 half-lives of agent) and agrees to not become participants in other experimental regimens (other than solely observational registries) for the duration of their participation in this trial (180 days).
Has been immunized with 2025-2026 COVID-19 vaccine (and later versions as they become available) between 1 and 26 weeks prior to randomization.
IPF duration \<10 years, based on the date of definitive diagnosis.
Ratio of forced expiratory volume in 1 second to forced vital capacity (FEV1/FVC) \>0.70

Usually NOT eligible if any of the following apply:

Exclusion Criteria:
Diagnoses of current infection by clinical or microbial assessments.
Diagnoses of an additional or alternative etiology for lung dysfunction based upon clinical assessment, including sepsis, congestive heart failure, thromboembolism, worsened pulmonary artery hypertension, etc. using routine clinical evaluations under direction of the attending physician.
History or serologic evidence of hepatitis B or C infection. Positive serology for Hepatitis C will not exclude patients if their circulating HC virus RNA test is negative.
Coagulopathy, defined as an INR \>1.6, PTT \>2x control, fibrinogen \<100 mg/dL, or platelet count \<50,000 unless these abnormalities can be reversed.
Uncontrolled diabetes or hypertension (systolic BP \>160 mm Hg and diastolic BP \>100 mm Hg) that would contraindicate use of corticosteroids.
Hemodynamic instability, defined as an inotrope or vasopressor requirement.
History of reactions to blood products, murine-derived products, or prior rituximab use within the last six months.
History of malignancy, excluding basal or squamous cell skin cancer and low-risk prostate cancer, the latter defined as stage T1 or T2a, with prostate specific antigen \<10 ng/dl. AART is not known to promote cancer, and these criteria are within current guidelines.
Unwillingness to accept blood product transfusion.
Diagnosis of major comorbidities expected to interfere with study participation.
Treatment for \>14 days within the preceding month with \>20 mg. prednisone (or equivalent) or any treatment during the last month with a cellular immuno-suppressant (e.g., cyclophosphamide, methotrexate, calcineurin inhibitors, etc.), or with rituximab (or other anti-B-cell biological agents) within the last 6 months.

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📞 Contact the Study Coordinator

Phone: (412) 215-6977

Email: srduncan@uabmc.edu

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Idiopathic Pulmonary Fibrosis

Atezolizumab for Idiopathic Pulmonary Fibrosis — Los Angeles, California
Phase 2 Clinical Trial of MNKD-201 (Nintedanib Dry Powder Inhalation) in Patients With Idiopathic Pulmonary Fibrosis — Windsor, Ontario
Metformin to Attenuate Progressive Respiratory Decline in Idiopathic Pulmonary Fibrosis — Worcester, Massachusetts
A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial) — Quilmes, Buenos Aires
Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for IPF — St John's,

Explore by condition: All Idiopathic Pulmonary Fibrosis clinical trials

💡 How to Participate

Check the checklist above to see if you may qualify.
Contact the study coordinator using the phone/email above.
Ask about the visit schedule, what is covered at no cost, and any travel support.
Confirm with your own doctor before making a decision.

🏛️ View Official NIH Record ↗